Skip to main content Skip to main menu
UF Health University of Florida
Division of Hematology & Oncology Department of Pediatrics in the College of Medicine
Jordan Milner

Jordan Milner, MD

Pediatric BMT and Cellular Therapy Program Director

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9120
Business Email: jordan.milner@ufl.edu
CV: View Curriculum Vitae

About Jordan Milner

Hello, my name is Jordan Milner, MD, and I am a clinical assistant professor in the division of pediatric hematology oncology at the University of Florida College of Medicine Department of Pediatrics. I became interested in medicine because of the wonderful relationships that are built between physicians and patients and because the field of medicine is always evolving and advancing. I chose pediatric bone marrow transplant (BMT) because I care about patients and helping them face complex underlying diseases.

In medical school, I was a member of the Global Scholar Program at St. George’s University School of Medicine for medical students who exhibit academic excellence. I completed my pediatric residency and chief year at Memorial University Medical Center in Savannah, GA, and went on to complete a fellowship in pediatric hematology/oncology at Maria Fareri Children’s Hospital at Westchester Medical Center in Valhalla, NY.

I have a strong passion for stem cell transplantation and cellular therapies and have dedicated my research to stem cell graft manipulation and virus specific cytotoxic T-lymphocytes. At the Pediatric Blood & Marrow Transplantation and Cell Therapy Program, we are currently working to bring alpha/beta T cell and B cell depletion for allogeneic stem cell transplants to UF and look forward to opening several trials utilizing this graft manipulation.

I look forward to continuing to serve as an advocate, helping to improve the curative treatment options for sickle cell disease and bring them to the University of Florida.

I am so happy to be a part of a team of innovative experts at the University of Florida. I am a native Floridian and I love to be outside with my family, especially by the water. I enjoy dancing and travelling abroad.

As a pediatric BMT and cellular therapy physician, I often times become a part of the patient’s family and enjoy advocating for what’s medically best for them. I look forward to providing outstanding and compassionate care to patients and their families here at UF Health.

Board Certifications

  • Pediatric Hematology-Oncology
    American Board of Pediatrics
  • Pediatrics
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML) – children
  • Aplastic anemia
  • Sickle Cell Disease

Research Profile

Dr. Milner’s research focus is graft manipulation. The utilization of graft manipulation permits decreased morbidities and improved quality of life in stem cell transplant recipients.

Areas of Interest
  • Allogeneic Hematopoietic Cell Transplantation
  • Bone marrow transplantation
  • Cellular Immunotherapy
  • Hematology
  • Hematology and Oncology
  • Hematopoietic Stem Cell Transplantation
  • Malignant Hematologic Disorders
  • Prevention of relapse following bone marrow transplantation
  • Sickle Cell Anemia

Publications

Academic Articles
2024
Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.
Leukemia research reports. 22 [DOI] 10.1016/j.lrr.2024.100472. [PMID] 39175509.
PubMed · Publisher’s Site
2024
Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial
Frontiers in Neurology. 15 [DOI] 10.3389/fneur.2024.1263373. [PMID] 38841694.
PubMed · Publisher’s Site
2024
The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.
Pediatric transplantation. 28(4) [DOI] 10.1111/petr.14784. [PMID] 38766976.
1 citation · PubMed · Publisher’s Site
2023
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
Blood. 142(24):2105-2118 [DOI] 10.1182/blood.2022019586. [PMID] 37562003.
16 citations · PubMed · Publisher’s Site
2022
Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients
Cureus. 14(9) [DOI] 10.7759/cureus.29195.
Publisher’s Site
2022
Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant
Bone Marrow Transplant. 57(4):586-592 [DOI] 10.1038/s41409-022-01584-y.
Publisher’s Site
2021
Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation
Bone Marrow Transplant. 56(9):2221-2230 [DOI] 10.1038/s41409-021-01298-7.
Publisher’s Site
2018
B-precursor Acute Lymphoblastic Leukemia Complicating 18q Deletion Syndrome
Pediatric Blood Cancer. 65(12) [DOI] 10.1002/pbc.27436.
Publisher’s Site
2009
Impact of physicians’ discomfort and patient prognosis on discussion of fertility preservation with young cancer patients
Patient Education and Counseling. 77(3):338-343

Grants

Jan 2025 ACTIVE
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
Role: Principal Investigator
Funding: PEDIATRIC BLOOD AND MARROW TRANSPLANT CO
Dec 2024 ACTIVE
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRa?+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediat
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via NATL INST OF HLTH NIAID
Sep 2024 ACTIVE
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP
Jul 2024 ACTIVE
CTOA Milner
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2024 ACTIVE
Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T-Cell and B-Cell Depletion for Pediatric, Adolescent, and Young Adults with Underlying Malignancies
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Jan 2024 ACTIVE
Clinical Outcomes of Pediatric MDS: A Retrospective Review by the North American Pediatric Aplastic Anemia Consortium (NAPAAC)
Role: Principal Investigator
Funding: CHILDRENS HOSPITAL COLORADO via SWIM ACROSS AMERICA
Sep 2023 ACTIVE
Genomic and Immunomic Mechanisms of Resistance During Daratumumab Post Stem Cell Transplantation in Patients with Poor-Risk T-Cell Lymphoblastic Lymphoma/Leukemia
Role: Principal Investigator
Funding: NEW YORK MEDICAL COLLEGE via US ARMY MED RES ACQUISITION
Jun 2023 ACTIVE
Utilization of Alpha/Beta T Cell and B Cell Depletion in Allogeneic Stem Cell Transplantation in Malignant Diseases
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
May 2023 – Apr 2025
Safety & Efficacy of Prophylactic Defibrotide Admin in CAYA w/Sickle Cell Disease or Beta Thalassemia Following MAC & Haplo Stem Cell Transplant Utilizing CD34 Enrichment & T-Cell(CD3) Addback
Role: Principal Investigator
Funding: NEW YORK MEDICAL COLLEGE via JAZZ PHARMACEUTICALS
Dec 2022 ACTIVE
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT)
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via NATL INST OF HLTH NHLBI
Apr 2022 ACTIVE
Engineered Donor Graft for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)- Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC) First Prospective Multicenter Trial
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Dec 2019 – Dec 2024
A Randomized Trial of Alpha 1-Antitrypsin (AAT) for Treatment of High Risk Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplant
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via NATL INST OF HLTH
Dec 2019 – Dec 2024
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via CSL BEHRING
Jul 2019 ACTIVE
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID receiving TCRaB+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatr
Role: Principal Investigator
Funding: CHILDRENS HOSP LOS ANGELES via NATL INST OF HLTH
May 2019 ACTIVE
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via NATL INST OF HLTH NHLBI
May 2019 ACTIVE
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Role: Principal Investigator
Funding: NATL MARROW DONOR PROG dba NMDP via NATL INST OF HLTH NHLBI
Sep 2018 – Jan 2025
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
Role: Principal Investigator
Funding: PEDIATRIC BLOOD AND MARROW TRANSPLANT CO
Aug 2017 – Feb 2025
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete R
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

Education

Pediatric Hematology/Oncology/BMT Fellowship
2017-2020 · Maria Fareri Children's Hospital at Westchester Medical Center
Pediatric Residency
2014-2017 · Memorial Health University Medical Center
Medical Degree
2014 · St. George's University School of Medicine
Bachelor of Science
2009 · University of South Florida

Contact Details

Phones:
Business:
(352) 273-9120
Emails:
Business:
jordan.milner@ufl.edu
Addresses:
Business Street:
1600 SW ARCHER RD
 GAINESVILLE FL 32610